SHANGHAI, April 7, 2026 /PRNewswire/ — Hip Hing Construction Company Ltd., along with Vibro (H.K.) Ltd. and CLPe, have been recognized at the International Innovation Awards (IIA) 2025, organized by Enterprise Asia, under the Service and Solution category for their pioneering solution, “Mobile MiC BIM CAVE”, an advanced BIM-driven Cave Automatic Virtual Environment that is transforming how construction professionals design, plan, train, and collaborate.

Developed to bridge the gap between virtual modelling and real-world construction execution, the BIM CAVE delivers a fully immersive, life-sized virtual environment using high-resolution projectors and LED screens across walls, ceilings, and floors. Unlike conventional VR systems reliant on individual headsets, Hip Hing’s BIM CAVE allows multiple stakeholders to simultaneously experience and interact with the digital building model, promoting collective understanding and real-time decision-making.

The system has been extensively deployed across three strategic application areas: training, virtual experience, and project facilitation. In training, it supports safety procedure instruction, awareness programmes for frontline staff, and skills development for technicians. For virtual experience, the BIM CAVE has enabled immersive show flat presentations and detailed aesthetic reviews, helping designers and end-users explore spatial layouts and design intent more effectively. In project facilitation, it provides a collaborative environment for constructability reviews, management coordination, and as-built status documentation, enhancing both efficiency and accuracy.

In 2024, Hip Hing advanced this innovation further with the launch of a mobile MiC (Modular Integrated Construction) BIM CAVE. Designed for flexibility and rapid deployment, the mobile unit significantly reduces the need for stakeholder travel while enabling seamless onsite collaboration. Through collaboration with CLPe, the mobile solution is powered by newly adopted high-energy output power banks and other advanced MiC technologies, enabling stable, high-performance operation in diverse environments.

By integrating training, visualization, and coordination into a single cohesive platform, the Mobilized BIM CAVE Experience reinforces Hip Hing’s commitment to digital transformation, operational excellence, and the future of smart, connected construction ecosystems.

About Enterprise Asia

Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine toward sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplifting the economic status of people across Asia and ensuring a legacy of hope, innovation, and courage for future generations. Please visit https://www.enterpriseasia.org/ for more information.

About the International Innovation Awards

The International Innovation Awards (IIA) is an annual recognition program that recognizes outstanding innovations, and in the process, encourages organizations to continue investing in innovations. For more information, visit www.innovationaward.org.

• Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products
• Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments
• Delivers near-term revenue and profitability with 2025 normalized revenue of US$82,232,000 (approximately RMB566,299,000) with an EBITDA of US$27,273,000 (approximately RMB187,818,000).
• Strong synergies with Everest’s existing portfolio and enhances Everest’s position as a regional partner of choice for Chinese and global innovative assets

SHANGHAI, April 8, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, EverSea Medicines (Singapore) Pte. Ltd., has entered into a Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited to conditionally acquire the entire equity interest in its wholly-owned subsidiary, Hasten Biopharmaceuticals (SG) Pte. Ltd.

The Acquisition will complement the Company’s existing pipeline, unlock significant synergies between its product portfolio and commercialization capabilities, strengthen its business profile, deepen its presence in strategically aligned markets, and further expand its scale and breadth of its business across the Asia Pacific region.

According to the agreement:

• The aggregate consideration is USD250,000,000 (approximately RMB1,721,650,000), payable in three installments. The first installment of USD150,000,000 (approximately RMB1,032,990,000), representing 60% of the consideration, payable at Closing, subject to the satisfaction or waiver of the conditions precedent to Closing. The second and third installments of USD50,000,000 each (approximately RMB344,330,000 each), representing 20% of the consideration respectively, are expected to become due and payable during the first quarter of 2028 and the first quarter of 2029, respectively, subject to the satisfaction or waiver of the conditions precedent applicable to each installment.
• The refundable deposit of RMB200,000,000 paid in accordance with the terms of the Letter of Intent shall be fully repaid by Hasten Biopharmaceuticals (Asia) Limited to the Company within 10 days after the Closing.
• Upon Closing, Hasten Biopharmaceuticals (SG) Pte. Ltd. will become an indirect wholly-owned subsidiary of the Company and its financial results will be consolidated into the Company’s financial statements.

The Acquisition includes the Marketing Authorization Holder (MAH) rights, trademark and broad commercial rights for 14 branded chronic disease products owned by Hasten Biopharmaceuticals (SG) Pte. Ltd. across multiple countries and regions in the Asia Pacific region. For the financial year ended 31 December 2025, Hasten Biopharmaceuticals (SG) Pte. Ltd. recorded a normalized revenue of US$82,232,000 (approximately RMB566,299,000) with an EBITDA of US$27,273,000 (approximately RMB187,818,000).

Hasten Biopharmaceuticals (SG) Pte. Ltd. is principally engaged in the commercialization of prescription pharmaceutical products, with a strategic focus on chronic diseases and acute/critical care, particularly in the cardiovascular and metabolic segments. It has established a mature pan-Asia-Pacific commercialization platform supported by an experienced local team of approximately 120 dedicated field forces. With over 2 billion people in the core Asia Pacific market, the Asia Pacific region has a large and growing patient base and continues to face substantial unmet medical needs, particularly in chronic disease management.

Everest’s product pipeline is focused on chronic disease therapeutic areas, including CKM (cardiovascular, kidney, and metabolic diseases), and the Company has established a leading innovative drug commercialization platform for chronic diseases in China. Beyond Mainland China, the Company’s commercialized products, including NEFECON^®, VELSIPITY^® and XERAVA^®, are progressing through new drugs application (NDA) approvals and reimbursement processes in authorized Asian markets. The Acquisition is expected to accelerate the commercialization of the Company’s existing products in Asian markets, support a faster ramp-up in overseas revenue contribution, and represent an important step in the Company’s broader regional expansion strategy.

The Company also believes that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. At the same time, regulatory pathways, market access frameworks and awareness of innovative therapies continue to improve. In such an environment, long-term success will depend not only on the quality of product assets, but also on the ability to build localized capabilities across regulatory, market access, medical affairs and commercialization which would create a competitive advantage for the Company in this growing region.

Everest Medicines is committed to becoming a leading global biopharmaceutical company in Asia. This acquisition would enable the Company to extend into the Asia Pacific region the commercialization capabilities it has already built and validated in China. This would allow the Company to strengthen its regional footprint, accelerate market entry and execution for both existing and future products, and build the infrastructure and local know-how required to support broader overseas expansion over time.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

About Hasten Biopharmaceuticals (Asia) Limited and Hasten Biopharmaceuticals (SG) Pte. Ltd.

Hasten Biopharmaceuticals (Asia) Limited is a company incorporated in the Cayman Islands with limited liability and is principally engaged in investment holding.

Hasten Biopharmaceuticals (SG) Pte. Ltd. is a company incorporated in Singapore with limited liability and principally engaged in commercialization of prescription pharmaceutical products with strategic focus on chronic diseases and acute/critical care areas, in particular in the cardiovascular and metabolism segments. Hasten Biopharmaceuticals (SG) Pte. Ltd. holds the asset rights, including Marketing Authorization Holder (MAH) rights, trademark and broad commercial rights for 14 branded chronic disease products across multiple countries and regions in the Asia Pacific region.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

BEIJING, April 8, 2026 /PRNewswire/ — A report from China Daily: Xi’an Jiaotong University is holding events to mark the 130th anniversary of its founding and the 70th anniversary of its westward relocation.

The university’s roots can be traced back to 1896 when the Nanyang Mission College was founded in Shanghai, which was renamed Chiao Tung University in 1921.

In response to the central government’s call, Chiao Tung University’s main body was relocated to Xi’an and rebranded as Xi’an Jiaotong University in 1959.

During his visit to XJTU in April 2020, the top Chinese leader noted the core of the Western Relocation Spirit is patriotism, and that its quintessence is following the instructions and guidance of the Party, breathing the same air and sharing a common destiny with the Party, the country and the people.

Inspired by this ethos, XJTU has made remarkable progress in education, research, social service, cultural inheritance and innovation, and international exchange.

Talent cultivation
XJTU now offers 77 undergraduate programs, with 45 first-level disciplines authorized to confer doctoral degrees, and 45 first-level disciplines authorized to confer master’s degrees. It also offers 10 professional doctoral programs and 32 professional master’s programs, and has 34 post-doctoral research mobile stations.

XJTU boasts eight national key first-level disciplines, eight national second-level disciplines, three key disciplines with national support and 166 national first-class undergraduate courses.

Latest data show the university has 265 bases at the provincial level or above, along with 12 national experimental teaching demonstration centers and nine national-level teaching teams. It also boasts one national teaching materials base and eight national teaching and training bases.

To align itself with the country’s development strategies, XJTU has established the School of Future Technology, the School of Modern Industry and the National School for Engineers.

As a national pioneer in AI-empowered education, XJTU rolled out the AI Pioneer Program in 2025, creating a comprehensive AI Plus education ecosystem. Its Project 101 for undergraduate education reform in AI underscores XJTU’s pursuit of cultivating innovative talents.

Throughout its history, XJTU has long served as a spiritual beacon illuminating wisdom, nurturing a large number of statesmen, scientists, social activists, educators, entrepreneurs, artists and medical experts, including Qian Xuesen (1911-2009), known as the “father of China’s aerospace”, and Zhang Guangdou (1912-2013), a trailblazer for China’s hydraulic engineering.

In recent years, its students have excelled in global competitions, such as the SAE Aero Design, the VEX Robotics Competition, the Chinese Debate World Cup and the International Collegiate Programming Contest.

Scientific research
Since its relocation to Xi’an, XJTU has emerged as a leader in scientific innovation. Its landmark contributions include China’s first engineering thermophysics institute, pioneering efforts in steam turbine engineering, energy storage, and the nation’s first large general-purpose electronic computer. The university also developed China’s first digital processing chip with independent intellectual property rights and the globally recognized twin-shear unified strength theory.

XJTU also plays a pivotal role in major national projects, including the Chang’e-5 lunar exploration mission, smart energy initiatives, and the development of large aircraft.

Its “6352” Industry-Education Integration Innovation Project enhances enterprise-academia collaboration, establishing joint research and incubation partnerships.

XJTU has introduced the “1121” cooperation model that features a joint research and development center, a business incubator, efforts around industry and innovation chains, and one shared platform for introducing, supporting and employing top-notch overseas talents through the joint effort of universities, enterprises and governments.

To date, XJTU has signed agreements with 255 leading enterprises, launched 100 deep university-enterprise innovation consortia, resolved 3,124 key technical challenges, and incubated 281 tech startups, provided significant contributions to China’s high-quality economic development.

Global engagement
Fostering international ties is a cornerstone of XJTU’s development strategy. The university has established 147 global undergraduate recruitment bases across 28 countries and regions, and spearheaded partnerships such as Xi’an Jiaotong-Liverpool University in 2006 and the XJTU-POLIMI Joint School with Politecnico di Milano in 2022.

In 2015, XJTU initiated the University Alliance of the Silk Road, a nongovernmental and nonprofit organization, connecting 207 universities in 45 countries and regions to promote education and cultural exchange.

The university also supports Shanghai Cooperation Organization goals. In 2025, it took over took over the responsibilities of the SCO University President’s Office (Chinese side) and jointly founded the Digital Education Alliance of SCO Countries and the China-SCO Higher Education Cooperation Center.

Campus culture
Dedicated to fostering a vibrant campus culture, XJTU has developed signature events such as the Cherry Blossom Festival and the Great Masters drama series. It supports 149 student clubs and hosts platforms like the World Affairs Forum and iHarbor Lectures to broaden intellectual horizons.

With its profound cultural legacy and robust cultural initiatives, XJTU has earned recognition as one of the first Scientist Spirit Education Bases and a National Cultural and Ethical Advanced Campus.

Its Culture Plus program enhances grassroots cultural integration, promoting values of integrity, inclusiveness, and innovation.

Social services
XJTU offers medical care through affiliated hospitals with their medical teams reaching out to such regions as the Xizang and Xinjiang Uygur autonomous regions. It emphasizes grassroots healthcare development and contributes to the advancement of the Healthy China Initiative.

The university has signed strategic agreements with 18 provincial-level regions to support development goals and and completed paired assistance programs with six universities, including Xin­jiang University.

Rooted in Western Relocation Spirit, XJTU excels as a beacon of education, research, culture and international collaboration. It remains dedicated to advancing both local and global communities, ensuring a legacy of excellence that transcends time.